Interviews - With Orphan Drug status and a largely-unmet medical need for its primary indication, ADVENTRX Pharmaceuticals (AMEX:ANX) expects its lead candidate, ANX-188, to be the company’s … Continue Reading
Read NowInterviews - Ventrus Biosciences (NASDAQ:VTUS) believes it has hit the “trifecta of anal fissure endpoints” with its lead candidate VEN-307. In a 465 patient Phase III trial, CEO … Continue Reading
Read NowInterviews - As the second-most prevalent cancer in the U.S. and 3rd leading cause of death, colorectal cancer and its treatment present a major market for Spectrum … Continue Reading
Read NowInterviews - Clinical trials and in-house drug development are expensive and time-consuming aspects of the biotechnology industry, but are nevertheless fixtures of standard business development. SciClone Pharmaceuticals … Continue Reading
Read NowInterviews - Abaxis (NASDAQ:ABAX) CEO Clint Severson discusses opportunities for growth and comments on the Federal Trade Commission’s (FTC) investigation into Idexx Laboratories’ (NASDAQ:IDXX) non-compete agreement with … Continue Reading
Read NowInterviews - Discussing Rigel Pharmaceutical’s (NASDAQ:RIGL) immunomodulatory Rheumatoid Arthritis (RA) treatment, CEO Jim Gower says it has the potential to replace TNF inhibitors as the standard-of-care, with … Continue Reading
Read NowInterviews - Scientists at Washington University in St. Louis, Missouri were studying two hormones – human Chorionic Gonadotropin (hCG) and Luteinizing Hormone (LH) – when they made … Continue Reading
Read Now